VRAX
Virax Biolabs Group Ltd.
NASDAQ · Healthcare · Biotechnology · GB
$1.40
−3.45%Year over year
Reported trailing growth
- Revenue
- +121.6%
- EBITDA
- -37.8%
- EBIT
- -45.8%
- EPS
- +39.7%
- Free cash flow
- -53.7%
- Operating cash flow
- -65.3%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +13.2%
- EBITDA
- +6.4%
- EBIT
- -3.8%
- Net income
- +17.1%
- EPS
- +74.2%
- Free cash flow
- +5.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026